Lymphoma, Follicular Clinical Trials

77 clinical trials for Lymphoma, Follicular across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) — RECRUITING · PHASE1
• A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) — RECRUITING · PHASE1
• Long-term Ovarian Fertility in Patients Treated for Lymphoma. — RECRUITING
• Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). — RECRUITING · PHASE1
• A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies — RECRUITING · PHASE1
• MOLyF : Bone Marrow and Follicular Lymphoma — RECRUITING · NA
• Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries — RECRUITING · PHASE2
• A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma — COMPLETED · PHASE2
• Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells — ACTIVE_NOT_RECRUITING
• A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies — NOT_YET_RECRUITING · NA
• Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell — COMPLETED
• A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan — ACTIVE_NOT_RECRUITING
• Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients — ACTIVE_NOT_RECRUITING · PHASE3
• Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine — COMPLETED · PHASE1
• A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial) — COMPLETED · PHASE2
• A Phase 1 Study of ADI-001 in B Cell Malignancies — TERMINATED · PHASE1
• Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. — WITHDRAWN · NA
• PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL — WITHDRAWN · PHASE1
• A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea — COMPLETED
• Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study — TERMINATED
• An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma — TERMINATED · PHASE2
• Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma — WITHDRAWN · PHASE1
• A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies — COMPLETED · PHASE1
• A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma — COMPLETED · PHASE2
• A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors — TERMINATED · PHASE1
• Safety Study of SEA-CD40 in Cancer Patients — TERMINATED · PHASE1
• Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma — COMPLETED · PHASE1
• A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma — COMPLETED · PHASE1
• Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) — COMPLETED · PHASE2
• Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) — COMPLETED · PHASE2
• Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma — COMPLETED · PHASE1
• A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma — COMPLETED · PHASE1
• Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL) — TERMINATED · PHASE3
• Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL — COMPLETED · PHASE1
• Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) — COMPLETED · PHASE1
• Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma — COMPLETED · PHASE2
• FCM Versus R-FCM Followed by R-Maintenance or Observation Only — OTHER · PHASE3
• Study of Lymphoma in Asia — COMPLETED
• Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma — OTHER · PHASE1
• A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma — COMPLETED · PHASE3
• A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma — COMPLETED · PHASE1
• Study of Prognosis of Follicular Lymphoma Through a Prospective Collection of Data (F2-study) — COMPLETED
• A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma — OTHER · PHASE2
• Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy — TERMINATED · PHASE3
• A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab — COMPLETED · PHASE1
• To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan — COMPLETED · PHASE3
• Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) — COMPLETED · PHASE2

Refine this search